Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFG316 in Transplant Associated Microangiopathy
NCT02763644Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of tesidolumab in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Novartis. Started Apr 2016; status: terminated.
02
Drugs
tesidolumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NCT02763644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763644.